[Comment] Multiple standards of care in non-small-cell lung cancer after EGFR-TKI therapy: progress, fragmentation, or inevitability?

The treatment landscape of EGFR-mutated non-small-cell lung cancer harbouring exon 19 deletion or L858R mutations has advanced remarkably over the past two decades. Although acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is inevitable in most patients, novel compounds such as bispecific antibodies and antibody–drug conjugates (ADCs) have expanded the armamentarium of options after EGFR-TKI therapy. Following the global MARIPOSA-2 trial that showed superior progression-free surviva